LY 2228820 - Ralimetinib |
| رقم الكتالوجGB40267 |
Potent p38 MAPK inhibitor (IC50: 7 and 3 nM for p38α and p38β MAPKs respectively); antitumor agent for the treatment of multiple myeloma (MM) patients by reducing skeletal events and enhancing cytotoxicity of bortezomib
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 862505-00-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Potent p38 MAPK inhibitor (IC50: 7 and 3 nM for p38α and p38β MAPKs respectively); antitumor agent for the treatment of multiple myeloma (MM) patients by reducing skeletal events and enhancing cytotoxicity of bortezomib
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *